Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $295.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +13 vs. previous quarter
- 93
- 13F valueReported value at the end of Q2 2026
- $93.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$59.0M
- No comparable prior period
- Free cash flow, FY2025
- -$52.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $234.0K
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.84M
- Shares sold short
- Change
- +219.7K
- +3.9% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding NAUT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NAUT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nautilus Biotechnology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 (view filing)4:53 PM ET | Jun 2 | 2 days | Andreessen Marc L and 5 others10% Owner | SSale | −5.00M | $2.35 | −$11.8M | −83.7%971.9K after | 2 lots |
| Mar 4, 2026 (view filing) | Mar 4 | Same day | Patel Sujal MCEO, President, and Secretary | PPurchase | +25.0K | $2.61 | +$65.3K | +0.2%10.4M after | |
| Nov 10, 2025 (view filing) | Nov 6 | 4 days | Suzuki KentaroChief Marketing Officer | PPurchase | +4.00K | $1.49 | +$5.96K | New position4.00K after | |
| Sep 9, 2025 (view filing) | Sep 5-8 | 4 days | Patel Sujal MCEO, President, and Secretary | PPurchase | +200.0K | $0.6742 | +$134.8K | +2.0%10.3M after | 2 lots |
| Sep 5, 2025 (view filing) | Sep 4 | 1 day | Murphy Matthew B.General Counsel | PPurchase | +20.0K | $0.64 | +$12.8K | +36.9%74.1K after | |
| Jun 2, 2025 (view filing) | May 29 | 4 days | Mowry AnnaCFO and Treasurer | PPurchase | +15.0K | $0.77 | +$11.6K | +22.1%83.0K after | |
| May 12, 2025 (view filing) | May 8-12 | 4 days | Mallick ParagChief Scientist | PPurchase | +13.5K | $0.73 | +$9.86K | +0.1%20.5M after | 2 lots |
| Mar 21, 2025 (view filing) | Mar 19-20 | 2 days | Patel Sujal MCEO, President, and Secretary | PPurchase | +77.2K | $0.9931 | +$76.7K | +0.8%10.1M after | 2 lots |
| Sep 25, 2024 (view filing)6:29 PM ET | Sep 23 | 2 days | Godwin Mary E.Senior VP, Operations | SSale | −47.0K | $2.87 | −$134.7K | −100.0%0 after | |
| Sep 18, 2024 (view filing)6:32 PM ET | Sep 17 | 1 day | Godwin Mary E.Senior VP, Operations | SSale | −35.0K | $2.85 | −$99.9K | −100.0%0 after |
Top 10 13F holders, Q2 2026
See all 93 holdersThe largest institutional positions in Nautilus Biotechnology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 11,634,211 | $21.8M | 0.34% | −960,000−7.6% | Reduced |
| AH Capital Management, L.L.C. | 9,063,054 | $16.9M | 0.12% | −8,590,863−48.7% | Reduced |
| Cercano Management LLC | 7,172,985 | $13.4M | 1.79% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,687,226 | $5.03M | 0.00% | +2,499,555+1,331.9% | Added |
| Vanguard Capital Management LLC | 2,549,979 | $4.77M | 0.00% | +4,382+0.2% | Added |
| Comprehensive Financial Management LLC | 2,207,619 | $4.13M | 0.14% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,896,192 | $3.55M | 0.00% | +1,896,192 | New |
| Geode Capital Management, LLC | 1,265,535 | $2.37M | 0.00% | +662,011+109.7% | Added |
| Acadian Asset Management LLC | 1,055,461 | $1.97M | 0.00% | +314,215+42.4% | Added |
| Clearstead Advisors, LLC | 892,787 | $1.67M | 0.02% | −1,436,997−61.7% | Reduced |
Holders of 5% or more of NAUT
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nautilus Biotechnology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Mallick Parag | 13D/A | 17.60%22.6M shares | +0.20 ppfrom 17.40% | Jun 16, 20213 filings | Mar 4, 2026 | SEC |
| Patel Sujal M | 13D/A | 16.30%21.2M shares | +0.60 ppfrom 15.70% | Jun 16, 20213 filings | Mar 4, 2026 | SEC |